Article List
List all articles in the database by earliest discovery_date
GET /articles/?format=api&page=2439
{ "count": 24559, "next": "http://api.gregory-ms.com/articles/?format=api&page=2440", "previous": "http://api.gregory-ms.com/articles/?format=api&page=2438", "results": [ { "article_id": 178, "title": "Efficacy of core stability versus task oriented trainings on balance in ataxic persons with multiple sclerosis. A single blinded randomized controlled trial", "summary": "<div><p>Mult Scler Relat Disord. 2021 Feb 23;50:102866. doi: 10.1016/j.msard.2021.102866. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">BACKGROUND: Balance and ataxic symptoms are commonly encountered in people with multiple sclerosis (PwMS). Many intervention approaches have been proposed to address balance in PwMS. The purpose of this study was to investigate the efficacy of adding core stability versus task oriented trainings on traditional approaches on balance in ataxic PwMS.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: Forty five ataxic relapsing-remitting PwMS from both sexes were randomly assigned into three identical groups. Control group (CG) treated with conventional balance exercise program; study groups I (GI) and II (GII) received respectively additional training using core stability exercises and task oriented trainings. Outcome measures recorded pre and post study period included stability index (SI), anterior posterior stability index (APSI), and mediolateral stability index (MLSI) using Biodex stability system in addition to the Berg balance scale (BBS).</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: Post treatment, the results indicated significant improvement in (SI) and (APSI) (p<0.05), and non-significant improvement (p>0.05) in (MLSI) and BBS in CG. In GI and GII there was a significant improvement in all balance measures (p<0.05). Comparison of post treatment results between groups indicated a significant improvement of GII compared to CG in all study measures, GI showed non- significant difference in all balance measures compared to the CG(P>0.05).</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSION: In PwMS balance rehabilitation should be multimodal; core stability exercises and task-oriented training in addition to conventional balance training are effective to improve balance and should be considered as an essential part of the training program for balance rehabilitation in ataxic PwMS. Task-oriented training in addition to conventional balance rehabilitation seem to be a favorable approach.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33652233/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210303021644&v=2.14.2\">33652233</a> | DOI:<a href=\"https://doi.org/10.1016/j.msard.2021.102866\">10.1016/j.msard.2021.102866</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33652233/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-05T00:00:00Z", "source": "PubMed", "publisher": "Elsevier BV", "container_title": "Multiple Sclerosis and Related Disorders", "authors": [ { "author_id": 240716, "given_name": "Ahmed S.", "family_name": "Ali", "ORCID": null, "country": null }, { "author_id": 240717, "given_name": "Moshera H.", "family_name": "Darwish", "ORCID": null, "country": null }, { "author_id": 240718, "given_name": "Nevin M.", "family_name": "Shalaby", "ORCID": null, "country": null }, { "author_id": 223884, "given_name": "Rami L.", "family_name": "Abbas", "ORCID": "http://orcid.org/0000-0002-6520-4069", "country": "LB" }, { "author_id": 240719, "given_name": "Habiba Z.", "family_name": "Soubhy", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-03T07:16:46Z", "noun_phrases": [ "Efficacy", "core stability", "task oriented trainings", "balance", "ataxic persons", "multiple sclerosis", "A single blinded randomized controlled trial" ], "doi": "10.1016/j.msard.2021.102866", "access": "restricted", "takeaways": " Balance and ataxic symptoms are commonly encountered in people with multiple sclerosis (PwMS) Many intervention approaches have been proposed to address balance in PwMS . Task-oriented training in addition to conventional balance rehabilitation seem to be a favorable approach .", "categories": [] }, { "article_id": 181, "title": "Exercise training and cognition in multiple sclerosis: The GET Smart trial protocol", "summary": "<div><p>Contemp Clin Trials. 2021 Feb 27:106331. doi: 10.1016/j.cct.2021.106331. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">BACKGROUND AND OBJECTIVES: Multiple sclerosis (MS) causes cognitive impairment in approximately 50% of cases. Disease modifying medications and cognitive rehabilitation produce only small positive effects on cognition in MS. Converging animal and human research suggests that aerobic exercise may improve cognition in people with MS, but definitive trials are lacking. We describe the design of the GET Smart study, a randomized controlled trial comparing the effects of aerobic exercise versus stretching and toning on cognition in MS.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: The study is a single-blind, parallel group randomized (1:1) controlled trial that compares aerobic exercise training with an active control group consisting of stretching and toning exercises for improving cognition. Participants are nondepressed, ambulatory, non-exercising adults with MS aged 18-54 years who have below average cognitive processing speed. Both treatments were designed to generate equivalent outcome expectancies and entailed supervised, progressive exercise programs, 3 times per week for up to 40 min over a 6 month period.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">PROJECTED PATIENT OUTCOMES: The primary hypothesis is that the aerobic training group will demonstrate significantly greater cognitive processing speed compared with the control group at the end of the treatment phase (6 months) as measured by a composite of the Paced Auditory Serial Additon Test and the oral Symbol-Digit Modalities Test using intent-to treat analyses. Secondary outcomes are neuropsychological functioning and cardiorespiratory fitness as well as participant reported outcomes such as depression, sleep, and fatigue. Study findings will inform future research, patient education, clinical care and policymaking.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT02106052.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33652128/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210303021644&v=2.14.2\">33652128</a> | DOI:<a href=\"https://doi.org/10.1016/j.cct.2021.106331\">10.1016/j.cct.2021.106331</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33652128/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-05T00:00:00Z", "source": "PubMed", "publisher": "Elsevier BV", "container_title": "Contemporary Clinical Trials", "authors": [ { "author_id": 240694, "given_name": "Charles H.", "family_name": "Bombardier", "ORCID": null, "country": null }, { "author_id": 157564, "given_name": "Robert W.", "family_name": "Motl", "ORCID": "http://orcid.org/0000-0003-0112-2803", "country": null }, { "author_id": 173959, "given_name": "Ralph H.B.", "family_name": "Benedict", "ORCID": "http://orcid.org/0000-0002-2080-3631", "country": null }, { "author_id": 240695, "given_name": "Nancy", "family_name": "Temkin", "ORCID": null, "country": null }, { "author_id": 240696, "given_name": "Peiqing", "family_name": "Qian", "ORCID": null, "country": null }, { "author_id": 240697, "given_name": "Katharine", "family_name": "Alexander", "ORCID": null, "country": null }, { "author_id": 240698, "given_name": "Annabeth", "family_name": "Evans", "ORCID": null, "country": null }, { "author_id": 240699, "given_name": "Andrea", "family_name": "Thomas", "ORCID": null, "country": null }, { "author_id": 240700, "given_name": "Kristin", "family_name": "Toms", "ORCID": null, "country": null }, { "author_id": 240701, "given_name": "Cathea M.", "family_name": "Carey", "ORCID": null, "country": null }, { "author_id": 240702, "given_name": "George H.", "family_name": "Kraft", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-03T07:16:46Z", "noun_phrases": [ "Exercise training", "cognition", "multiple sclerosis", "The GET Smart trial protocol" ], "doi": "10.1016/j.cct.2021.106331", "access": "restricted", "takeaways": " Multiple sclerosis causes cognitive impairment in approximately 50% of cases . Disease modifying medications and cognitive rehabilitation produce only small positive effects on cognition in MS . Study findings will inform future research, patient education, clinical care and policymaking .", "categories": [] }, { "article_id": 176, "title": "A man with erythematosquamous plaques", "summary": "<div><p style=\"color: #4aa564;\">Ned Tijdschr Geneeskd. 2021 Feb 18;165:D5795.</p><p><b>ABSTRACT</b></p><p xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\">A 43-year-old male visited our dermatology department with a skin eruption diagnosed as psoriasis. It began 1 month after starting peg-interferon-α-1a therapy for multiple sclerosis. Peg-interferon is known to be able to induce psoriasis, as well as other medication, while the pathophysiology remains unclear.</p><p style=\"color: lightgray\">PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33651510/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210302193644&v=2.14.2\">33651510</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33651510/", "published_date": "2021-02-18T00:00:00Z", "source": "PubMed", "publisher": null, "container_title": null, "authors": [], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-03T00:36:46Z", "noun_phrases": [ "A man", "erythematosquamous plaques" ], "doi": null, "access": "unknown", "takeaways": "", "categories": [] }, { "article_id": 177, "title": "Validity of the Italian multiple sclerosis neuropsychological screening questionnaire", "summary": "<div><p>Neurol Sci. 2021 Mar 2. doi: 10.1007/s10072-021-05141-1. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">The Multiple Sclerosis Neuropsychological Questionnaire (MSNQ) is a brief questionnaire useful for screening patients with multiple sclerosis (MS) at risk for cognitive impairment. It includes a patient self-assessment (MSNQ-p) and a section for the caregiver (informant) (MSNQ-i). This study's aim was to validate the Italian version of MSNQ and to compare MSNQ scores with Symbol Digit Modality Test (SDMT), Beck Depression Inventory (BDI), and Expanded Disability Status Scale (EDSS) score, measuring cognitive skills, mood status, and physical disability respectively. We enrolled 122 MS patients (and related caregivers) at MS center of Tor Vergata University Hospital of Rome. The final study sample consisted of 122 patients with MS (90 relapsing-remitting, 24 secondary progressive, and 8 primary progressive). Our results highlighted that MSNQ has a unidimensional factor structure. Correlational analyses found a good correlation between both versions (MSNQ-p and MSNQ-i) of the questionnaire. Both MSNQ-p and MSNQ-i were correlated with clinical variables, specifically with cognitive impairment, mood disorder, and with disability. The Italian version of MSNQ is reliable and useful as screening tool to identify MS patients at high risk of cognitive impairment.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33651198/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210302193644&v=2.14.2\">33651198</a> | DOI:<a href=\"https://doi.org/10.1007/s10072-021-05141-1\">10.1007/s10072-021-05141-1</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33651198/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-11T00:00:00Z", "source": "PubMed", "publisher": "Springer Science and Business Media LLC", "container_title": "Neurological Sciences", "authors": [ { "author_id": 221823, "given_name": "Simone", "family_name": "Migliore", "ORCID": "http://orcid.org/0000-0002-2665-231X", "country": null }, { "author_id": 244543, "given_name": "Doriana", "family_name": "Landi", "ORCID": null, "country": null }, { "author_id": 297371, "given_name": "Francesca", "family_name": "Proietti", "ORCID": null, "country": null }, { "author_id": 300978, "given_name": "Giulia", "family_name": "D’Aurizio", "ORCID": null, "country": null }, { "author_id": 300979, "given_name": "Ferdinando", "family_name": "Squitieri", "ORCID": null, "country": null }, { "author_id": 246761, "given_name": "Giorgia", "family_name": "Mataluni", "ORCID": null, "country": null }, { "author_id": 244567, "given_name": "Carolina Gabri", "family_name": "Nicoletti", "ORCID": null, "country": null }, { "author_id": 297372, "given_name": "Giuseppe", "family_name": "Curcio", "ORCID": null, "country": null }, { "author_id": 207541, "given_name": "Girolama Alessandra", "family_name": "Marfia", "ORCID": "http://orcid.org/0000-0001-5863-7758", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-03T00:36:46Z", "noun_phrases": [ "Validity", "the Italian multiple sclerosis", "neuropsychological screening questionnaire" ], "doi": "10.1007/s10072-021-05141-1", "access": "restricted", "takeaways": " Multiple Sclerosis Neuropsychological Questionnaire (MSNQ) is a brief questionnaire useful for screening patients with multiple sclerosis at risk for cognitive impairment . It includes a patient self-assessment and a section for the caregiver (informant)", "categories": [] }, { "article_id": 174, "title": "Untreated patients with multiple sclerosis: a study of French expert centers", "summary": "<div><p>Eur J Neurol. 2021 Mar 1. doi: 10.1111/ene.14790. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">BACKGROUND: Disease modifying therapies (DMTs), have an impact on relapses and disease progression. Nonetheless, many patients with multiple sclerosis (pwMS) remain untreated. The objective of the present study was to determine the proportion of untreated patients with multiple sclerosis (pwMS) followed in expert centers in France and determine the predictive factors of non-treatment.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: Retrospective cohort study. Data were extracted from the 38 centers participating in the European Database for Multiple Sclerosis (EDMUS) on 12/15/2018 and pwMS seen at least once during the study period (from June 15, 2016 to June 14, 2017) were included. Results Among the 21,189 pwMS (age 47.1±13.1; EDSS 3.4±2.4), 6,631 (31.3%; 95%CI=30.7-31.9) of the patients were not receiving any DMT. Although patients with a relapsing-remitting course (n = 11,693) were the most likely to receive DMT, 14.8% (95%CI = 14.2-15.4) were still untreated (6.8% never treated). After multivariate analysis among relapsing-remitting pwMS, the main factors explaining never having been treated were not having ≥9 lesions on brain MRI (OR = 0.52 [0.44-0.61]) and lower EDSS (OR = 0.78 [0.74-0.82]). Most patients with progressive MS (50.4% for secondary and 64.2% for primary progressive MS) did not receive any DMT during the study period, 11.6% for secondary and 34.0% for primary progressive MS had never received any DMT.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSION: A significant proportion of pwMS did not receive any DMT, even though such treatments are reimbursed by the healthcare system for French patients. This result highlights the unmet need for current DMTs for a large subgroup of pwMS.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33650261/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210302181644&v=2.14.2\">33650261</a> | DOI:<a href=\"https://doi.org/10.1111/ene.14790\">10.1111/ene.14790</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33650261/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-06T00:00:00Z", "source": "PubMed", "publisher": "Wiley", "container_title": "European Journal of Neurology", "authors": [ { "author_id": 149927, "given_name": "Xavier", "family_name": "Moisset", "ORCID": "http://orcid.org/0000-0002-8799-0750", "country": null }, { "author_id": 240663, "given_name": "Audrey‐Anne", "family_name": "Fouchard", "ORCID": null, "country": null }, { "author_id": 240664, "given_name": "Bruno", "family_name": "Pereira", "ORCID": null, "country": null }, { "author_id": 240665, "given_name": "Frédéric", "family_name": "Taithe", "ORCID": null, "country": null }, { "author_id": 149930, "given_name": "Guillaume", "family_name": "Mathey", "ORCID": "http://orcid.org/0000-0002-5747-9169", "country": null }, { "author_id": 168069, "given_name": "Gilles", "family_name": "Edan", "ORCID": "http://orcid.org/0000-0002-9641-6734", "country": null }, { "author_id": 149104, "given_name": "Jonathan", "family_name": "Ciron", "ORCID": "http://orcid.org/0000-0002-3386-6308", "country": "FR" }, { "author_id": 164938, "given_name": "Bruno", "family_name": "Brochet", "ORCID": "http://orcid.org/0000-0003-3824-2796", "country": "FR" }, { "author_id": 240666, "given_name": "Jérôme", "family_name": "De Sèze", "ORCID": null, "country": null }, { "author_id": 143476, "given_name": "Caroline", "family_name": "Papeix", "ORCID": "http://orcid.org/0000-0003-4074-6125", "country": null }, { "author_id": 166338, "given_name": "Patrick", "family_name": "Vermersch", "ORCID": "http://orcid.org/0000-0003-0997-8817", "country": null }, { "author_id": 169730, "given_name": "Pierre", "family_name": "Labauge", "ORCID": "http://orcid.org/0000-0001-7759-8555", "country": null }, { "author_id": 240668, "given_name": "Christine", "family_name": "Lebrun‐Frenay", "ORCID": null, "country": null }, { "author_id": 240669, "given_name": "Thibault", "family_name": "Moreau", "ORCID": null, "country": null }, { "author_id": 240670, "given_name": "David", "family_name": "Laplaud", "ORCID": null, "country": null }, { "author_id": 182588, "given_name": "Eric", "family_name": "Berger", "ORCID": "http://orcid.org/0000-0002-5003-9793", "country": null }, { "author_id": 324605, "given_name": "Jean", "family_name": "Pelletier", "ORCID": "http://orcid.org/0000-0001-9730-7567", "country": null }, { "author_id": 149339, "given_name": "Bruno", "family_name": "Stankoff", "ORCID": "http://orcid.org/0000-0002-9631-4674", "country": null }, { "author_id": 182589, "given_name": "Olivier", "family_name": "Gout", "ORCID": "http://orcid.org/0000-0001-6435-0761", "country": null }, { "author_id": 176046, "given_name": "Eric", "family_name": "Thouvenot", "ORCID": "http://orcid.org/0000-0001-8671-7747", "country": "FR" }, { "author_id": 318069, "given_name": "Olivier", "family_name": "Heinzlef", "ORCID": "http://orcid.org/0000-0002-4634-8542", "country": null }, { "author_id": 240672, "given_name": "Abdullatif", "family_name": "Al‐Khedr", "ORCID": null, "country": null }, { "author_id": 176047, "given_name": "Bertrand", "family_name": "Bourre", "ORCID": "http://orcid.org/0000-0002-2459-2480", "country": null }, { "author_id": 240673, "given_name": "Olivier", "family_name": "Casez", "ORCID": null, "country": null }, { "author_id": 240674, "given_name": "Philippe", "family_name": "Cabre", "ORCID": null, "country": null }, { "author_id": 149933, "given_name": "Alexis", "family_name": "Montcuquet", "ORCID": "http://orcid.org/0000-0002-7202-0399", "country": null }, { "author_id": 149934, "given_name": "Alain", "family_name": "Créange", "ORCID": "http://orcid.org/0000-0003-3838-1622", "country": "FR" }, { "author_id": 149935, "given_name": "Jean‐Philippe", "family_name": "Camdessanché", "ORCID": "http://orcid.org/0000-0002-5282-6707", "country": "FR" }, { "author_id": 240675, "given_name": "Serge", "family_name": "Bakchine", "ORCID": null, "country": null }, { "author_id": 240676, "given_name": "Aude", "family_name": "Maurousset", "ORCID": null, "country": null }, { "author_id": 240677, "given_name": "Karolina", "family_name": "Hankiewicz", "ORCID": null, "country": null }, { "author_id": 182593, "given_name": "Corinne", "family_name": "Pottier", "ORCID": "http://orcid.org/0000-0001-5422-7364", "country": null }, { "author_id": 149120, "given_name": "Nicolas", "family_name": "Maubeuge", "ORCID": "http://orcid.org/0000-0002-1618-6079", "country": null }, { "author_id": 240678, "given_name": "Dalia", "family_name": "Dimitri Boulos", "ORCID": null, "country": null }, { "author_id": 240679, "given_name": "Chantal", "family_name": "Nifle", "ORCID": null, "country": null }, { "author_id": 147248, "given_name": "Sandra", "family_name": "Vukusic", "ORCID": "http://orcid.org/0000-0001-7337-7122", "country": null }, { "author_id": 324604, "given_name": "Pierre", "family_name": "Clavelou", "ORCID": "http://orcid.org/0000-0003-2363-9352", "country": null }, { "author_id": 330404, "given_name": "Gilles", "family_name": "Defer", "ORCID": "http://orcid.org/0000-0003-1343-5858", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-02T23:16:45Z", "noun_phrases": [ "Untreated patients", "multiple sclerosis", "a study", "French expert centers" ], "doi": "10.1111/ene.14790", "access": "open", "takeaways": " Many patients with multiple sclerosis (pwMS) remain untreated . Disease modifying therapies (DMTs) have an impact on relapses and disease progression . Most patients with progressive MS did not receive any DMT during the study period .", "categories": [] }, { "article_id": 172, "title": "Metformin Protects Myelin from Degeneration in A Mouse Model of Iysophosphatidylcholine-Induced Demyelination in The Optic Chiasm", "summary": "<div><p>Cell J. 2021 Apr;23(1):119-128. doi: 10.22074/cellj.2021.7174. Epub 2021 Mar 1.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">OBJECTIVE: Multiple sclerosis (MS) is a demyelinating disease of the central nervous system. The autoimmune pathology and long-term inflammation lead to substantial demyelination. These events lead to a substantial loss of oligodendrocytes (OLs), which in a longer period, results in axonal loss and long-term disabilities. Neural cells protection approaches decelerate or inhibit the disease progress to avoid further disability. Previous studies showed that metformin has beneficial effects against neurodegenerative conditions. In this study, we examined possible protective effects of metformin on toxin-induced myelin destruction in adult mice brains.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">MATERIALS AND METHODS: In this experimental study, lysophosphatidylcholine (LPC) was used to induce demyelination in mice optic chiasm. We examined the extent of demyelination at different time points post LPC injection using myelin staining and evaluated the severity of inflammation. Functional state of optic pathway was evaluated by visual evoked potential (VEP) recording.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: Metformin attenuated LPC-induced demyelination (P<0.05) and inflammation (P<0.05) and protected against significant decrease (P<0.05) in functional conductivity of optic tract. These data indicated that metformin administration attenuates the myelin degeneration following LPC injection which led to functional enhancement.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSION: Our findings suggest metformin for combination therapy for patients suffering from the myelin degenerative diseases, especially multiple sclerosis; however, additional mechanistic studies are required.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33650828/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210302181644&v=2.14.2\">33650828</a> | DOI:<a href=\"https://doi.org/10.22074/cellj.2021.7174\">10.22074/cellj.2021.7174</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33650828/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-04T00:00:00Z", "source": "PubMed", "publisher": null, "container_title": null, "authors": [], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-02T23:16:45Z", "noun_phrases": [ "Metformin", "Myelin", "Degeneration", "A Mouse Model", "Iysophosphatidylcholine-Induced Demyelination", "The Optic Chiasm" ], "doi": "10.22074/cellj.2021.7174", "access": "restricted", "takeaways": " Multiple sclerosis (MS) is a demyelinating disease of the central nervous system . Previous studies showed that metformin has beneficial effects against neurodegenerative conditions .", "categories": [ { "category_id": 6, "category_description": "", "category_name": "Metformin", "category_slug": "metformin", "category_terms": [ "metformin" ], "article_count": 22 } ] }, { "article_id": 173, "title": "Development of a Web-Based Mindfulness Program for People With Multiple Sclerosis: Qualitative Co-Design Study", "summary": "<div><p>J Med Internet Res. 2021 Mar 2;23(3):e19309. doi: 10.2196/19309.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">BACKGROUND: Mindfulness-based stress reduction is an efficacious treatment for people with chronic health problems; however, it is highly intensive and time-consuming, which is a barrier for service provision.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">OBJECTIVE: This study aims to develop an internet-delivered adapted version of mindfulness-based stress reduction for people with multiple sclerosis to make the intervention more accessible.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: We co-designed a web-based mindfulness program with end users, that is, people with multiple sclerosis (N=19). Iterative feedback was also collected from a subsample of the initial group of end users (n=11), and the program was reviewed by experts (n=8).</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: We identified three main themes common to people with multiple sclerosis: dealing with uncertainty and fears for the future, grief and loss, and social isolation. These themes were incorporated into narratives throughout the program. People with multiple sclerosis who reviewed the program gave feedback that the program was relatable, feasible, and acceptable. Experts agreed that the program appropriately represented the main tenets of mindfulness. Iterative feedback was used to further refine the program.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSIONS: The web-based mindfulness program that we developed was viewed positively by both experts and end users. The program reflects common concerns for people with multiple sclerosis and has the potential to meet important unmet psychological needs. A randomized controlled trial was planned to determine the efficacy of the program.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33650980/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210302181644&v=2.14.2\">33650980</a> | DOI:<a href=\"https://doi.org/10.2196/19309\">10.2196/19309</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33650980/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-03-02T00:00:00Z", "source": "PubMed", "publisher": "JMIR Publications Inc.", "container_title": "Journal of Medical Internet Research", "authors": [ { "author_id": 225055, "given_name": "Amy-Lee", "family_name": "Sesel", "ORCID": "http://orcid.org/0000-0002-9698-2699", "country": null }, { "author_id": 227779, "given_name": "Louise", "family_name": "Sharpe", "ORCID": "http://orcid.org/0000-0002-8790-6272", "country": null }, { "author_id": 227780, "given_name": "Heidi N", "family_name": "Beadnall", "ORCID": "http://orcid.org/0000-0003-3734-4133", "country": null }, { "author_id": 148639, "given_name": "Michael H", "family_name": "Barnett", "ORCID": "http://orcid.org/0000-0002-2156-8864", "country": null }, { "author_id": 225057, "given_name": "Marianna", "family_name": "Szabo", "ORCID": "http://orcid.org/0000-0002-8825-7921", "country": null }, { "author_id": 227781, "given_name": "Sharon L", "family_name": "Naismith", "ORCID": "http://orcid.org/0000-0001-9076-2778", "country": "AU" } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-02T23:16:45Z", "noun_phrases": [ "Development", "a Web-Based Mindfulness Program", "People", "Multiple Sclerosis", "Qualitative Co-Design Study" ], "doi": "10.2196/19309", "access": "open", "takeaways": " Mindfulness-based stress reduction is an efficacious treatment for people with chronic health problems . However, it is highly intensive and time-consuming, which is a barrier for service provision . We developed a web-based mindfulness program with end users, that is, people with multiple sclerosis . We identified three themes common to people with MS: dealing with uncertainty and fears for the future, grief and loss .", "categories": [] }, { "article_id": 171, "title": "Neuroimmunology of COVID-19", "summary": "<div><p>Nervenarzt. 2021 Mar 2. doi: 10.1007/s00115-021-01077-1. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">Many neuroimmunological diseases, such as encephalopathy, encephalitis, myelitis and acute disseminated encephalomyelitis (ADEM) have occurred more frequently after infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which indicates a parainfectious or postinfectious association. The most likely underlying mechanisms include virus-triggered overactivation of the immune system with hyperinflammation and cytokine storm but potentially also the development of specific autoantibodies against central nervous system (CNS) tissue. These were predominantly detected in the cerebrospinal fluid of severely ill coronavirus disease 2019 (COVID-19) patients. In contrast, direct damage after invasion of SARS-CoV‑2 into the brain and spinal cord does not seem to play a relevant role. Susceptibility to infection with SARS-CoV‑2 in patients with multiple sclerosis, myasthenia or other neuroimmunological diseases including the risk for severe disease courses, is not determined by the administered immunotherapy but by known risk factors, such as age, comorbidities and the disease-related degree of disability. Therefore, immunotherapy in these patients should not be delayed or discontinued. The contribution of neuroimmunological mechanisms to long-term sequelae after survival of a COVID-19 illness, such as fatigue, impairment of memory, sleep dysfunction or anxiety, will require long-term clinical follow-up, preferentially in COVID-19 register studies.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33651117/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210302181644&v=2.14.2\">33651117</a> | DOI:<a href=\"https://doi.org/10.1007/s00115-021-01077-1\">10.1007/s00115-021-01077-1</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33651117/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-06T00:00:00Z", "source": "PubMed", "publisher": "Springer Science and Business Media LLC", "container_title": "Der Nervenarzt", "authors": [ { "author_id": 212886, "given_name": "Thomas", "family_name": "Skripuletz", "ORCID": "http://orcid.org/0000-0001-8550-335X", "country": null }, { "author_id": 240648, "given_name": "Nora", "family_name": "Möhn", "ORCID": null, "country": null }, { "author_id": 240649, "given_name": "Christiana", "family_name": "Franke", "ORCID": null, "country": null }, { "author_id": 240650, "given_name": "Harald", "family_name": "Prüß", "ORCID": null, "country": null } ], "relevant": false, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-02T23:16:45Z", "noun_phrases": [ "Neuroimmunology", "COVID-19" ], "doi": "10.1007/s00115-021-01077-1", "access": "open", "takeaways": " Many neuroimmunological diseases, such as encephalopathy, encephalitis, myelitis and acute disseminated encephalomyelitis (ADEM) have occurred more frequently after infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) The most likely underlying mechanisms include virus-triggered overactivation of the immune system .", "categories": [] }, { "article_id": 175, "title": "Benign monomelic amyotrophy of lower limb in a cohort of chinese patients", "summary": "<div><p>Brain Behav. 2021 Mar 2:e02073. doi: 10.1002/brb3.2073. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">BACKGROUND: Benign monomelic amyotrophy of lower limb (BMALL) is a neurogenic syndrome representing an unclear field. Further studies might be helpful to elucidate uncertainties regarding causation, outcome, and the risk of progression to amyotrophic lateral sclerosis (ALS).</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: According to the inclusion and exclusion criteria, 37 patients with BMALL were retrospectively collected in three neuromuscular centers from January 2012 to October 2018. The detailed medical data were summarized. Multiple laboratory tests were examined. Routine electrophysiological examinations, muscle MRI of lower limbs, and muscle biopsy were conducted.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: The cohort included 24 male and 13 female cases with median age of onset 47 years. Muscle MRI revealed that the distribution of involved muscles matched with the extent of fat infiltration, so the pattern muscle atrophy can be divided into the following four types: six patients with thigh atrophy (type I), 14 patients with leg atrophy (type II); 10 patients with disproportionate atrophy in both thigh and leg (type III); and seven patients with well-proportionate atrophy in both thigh and leg (type IV). Electrophysiological findings showed neurogenic pattern, spontaneous activity, and abnormal H reflex, which suggested a disorder of spinal anterior horn cell in the patients with types I-III. However, no electrophysiological abnormalities were found in the patients with type IV. Muscle pathology varied from almost normal pattern to advanced neurogenic pattern in nine biopsied patients. Follow-up showed that two patients with type II developed to ALS four years later, and all patients with type IV were in stable condition without any complaints.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSION: Muscle MRI was useful to exactly localize the distribution of involved muscles in BMALL patients. The distribution of atrophic muscles can be roughly divided into four types based on the MRI features. The classification of distributing types might be as an indicator for the prognosis of BMALL.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33650811/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210302181644&v=2.14.2\">33650811</a> | DOI:<a href=\"https://doi.org/10.1002/brb3.2073\">10.1002/brb3.2073</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33650811/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-04T00:00:00Z", "source": "PubMed", "publisher": "Wiley", "container_title": "Brain and Behavior", "authors": [ { "author_id": 240637, "given_name": "Lulu", "family_name": "Wang", "ORCID": null, "country": null }, { "author_id": 240638, "given_name": "Han", "family_name": "Wen", "ORCID": null, "country": null }, { "author_id": 240639, "given_name": "Shuyun", "family_name": "Chen", "ORCID": null, "country": null }, { "author_id": 191457, "given_name": "Huan", "family_name": "Wang", "ORCID": "http://orcid.org/0000-0002-3816-9552", "country": "CN" }, { "author_id": 240640, "given_name": "Yilei", "family_name": "Zheng", "ORCID": null, "country": null }, { "author_id": 240641, "given_name": "Ran", "family_name": "Chen", "ORCID": null, "country": null }, { "author_id": 240642, "given_name": "Jingjing", "family_name": "Li", "ORCID": null, "country": null }, { "author_id": 240643, "given_name": "Kaiyan", "family_name": "Jiang", "ORCID": null, "country": null }, { "author_id": 240644, "given_name": "Haijie", "family_name": "Xiang", "ORCID": null, "country": null }, { "author_id": 240645, "given_name": "Min", "family_name": "Zhu", "ORCID": null, "country": null }, { "author_id": 240646, "given_name": "Meihong", "family_name": "Zhou", "ORCID": null, "country": null }, { "author_id": 240647, "given_name": "Sheng", "family_name": "Yao", "ORCID": null, "country": null }, { "author_id": 209914, "given_name": "Daojun", "family_name": "Hong", "ORCID": "http://orcid.org/0000-0003-1380-3534", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-02T23:16:45Z", "noun_phrases": [ "Benign monomelic amyotrophy", "lower limb", "a cohort", "chinese patients" ], "doi": "10.1002/brb3.2073", "access": "open", "takeaways": " Benign monomelic amyotrophy of lower limb (BMALL) is a neurogenic syndrome representing an unclear field . Muscle MRI revealed that the distribution of involved muscles matched with the extent of fat infiltration .", "categories": [] }, { "article_id": 168, "title": "Nrf2 through Aryl Hydrocarbon Receptor Regulates IL-22 Response in CD4+ T Cells", "summary": "<div><p>J Immunol. 2021 Mar 1:ji1900656. doi: 10.4049/jimmunol.1900656. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">IL-17A and IL-22 derived from Th17 cells play a significant role in mucosal immunity and inflammation. TGF-β and IL-6 promote Th17 differentiation; however, these cytokines have multiple targets. The identification and screening of additional molecules that regulate IL-17A and IL-22 responses in certain inflammatory conditions is of great clinical significance. In this study, we show that CDDO-Im, a specific Nrf2 activator, promotes IL-17A and IL-22 responses in murine Th17 cells. In contrast, CDDO-Im inhibits IL-17A response in multiple sclerosis patient-derived PBMCs. However, Nrf2 specifically regulates IL-22 response in vivo. Nrf2 acts through the regulation of antioxidant response element (ARE) binding motifs in target genes to induce or repress transcription. Promoter analysis revealed that <i>Il17a</i>, <i>Rorc</i>, and <i>Ahr</i> genes have several ARE motifs. We showed that Nrf2 bound to ARE repressor (ARE-R2) of <i>Rorc</i> and inhibited <i>Rorc</i>-dependent IL-17A transactivation. The luciferase reporter assay data showed that CDDO-Im regulated <i>Ahr</i> promoter activity. Chromatin immunoprecipitation quantitative PCR data showed that Nrf2 bound to ARE of AhR. Finally, we confirmed that the CDDO-Im-mediated induction of IL-22 production in CD4<sup>+</sup> T cells was abrogated in CD4-specific <i>Ahr</i> knockout mice (<i>Ahr<sup>CD4</sup></i> ). CH-223191, a specific AhR antagonist, inhibits CDDO-Im-induced IL-22 production in CD4<sup>+</sup> T cells, which further confirmed the AhR-dependent regulation. Collectively, our data showed that Nrf2 via AhR pathways regulated IL-22 response in CD4<sup>+</sup> T cells.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33648937/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210302080909&v=2.14.2\">33648937</a> | DOI:<a href=\"https://doi.org/10.4049/jimmunol.1900656\">10.4049/jimmunol.1900656</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33648937/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-03-31T23:00:00Z", "source": "PubMed", "publisher": "The American Association of Immunologists", "container_title": "The Journal of Immunology", "authors": [ { "author_id": 159147, "given_name": "Xun", "family_name": "Lin", "ORCID": "http://orcid.org/0000-0003-1860-3996", "country": null }, { "author_id": 240681, "given_name": "Suzanne", "family_name": "Tawch", "ORCID": null, "country": null }, { "author_id": 240682, "given_name": "Hoi Tong", "family_name": "Wong", "ORCID": null, "country": null }, { "author_id": 175667, "given_name": "Suyasha", "family_name": "Roy", "ORCID": "http://orcid.org/0000-0002-0332-4962", "country": null }, { "author_id": 240683, "given_name": "Stephen", "family_name": "Gaudino", "ORCID": null, "country": null }, { "author_id": 159152, "given_name": "Patricia", "family_name": "Castillo", "ORCID": "http://orcid.org/0000-0001-6290-4361", "country": null }, { "author_id": 159153, "given_name": "Waleed", "family_name": "Elsegeiny", "ORCID": "http://orcid.org/0000-0003-1170-4890", "country": "US" }, { "author_id": 159154, "given_name": "Nobunao", "family_name": "Wakabayashi", "ORCID": "http://orcid.org/0000-0003-4643-7841", "country": "US" }, { "author_id": 159155, "given_name": "Tim D.", "family_name": "Oury", "ORCID": "http://orcid.org/0000-0002-4253-3214", "country": null }, { "author_id": 159156, "given_name": "Derek", "family_name": "Pociask", "ORCID": "http://orcid.org/0000-0002-1256-6410", "country": null }, { "author_id": 159157, "given_name": "Kong", "family_name": "Chen", "ORCID": "http://orcid.org/0000-0001-6980-5454", "country": null }, { "author_id": 240684, "given_name": "Nancy", "family_name": "McLinskey", "ORCID": null, "country": null }, { "author_id": 159159, "given_name": "Patricia", "family_name": "Melville", "ORCID": "http://orcid.org/0000-0002-5754-6560", "country": null }, { "author_id": 240685, "given_name": "Olga", "family_name": "Syritsyna", "ORCID": null, "country": null }, { "author_id": 240686, "given_name": "Patricia", "family_name": "Coyle", "ORCID": null, "country": null }, { "author_id": 159162, "given_name": "Misty", "family_name": "Good", "ORCID": "http://orcid.org/0000-0002-0264-5721", "country": null }, { "author_id": 159163, "given_name": "Amit", "family_name": "Awasthi", "ORCID": "http://orcid.org/0000-0002-2563-1971", "country": null }, { "author_id": 159164, "given_name": "Jay K.", "family_name": "Kolls", "ORCID": "http://orcid.org/0000-0001-5151-6304", "country": null }, { "author_id": 240687, "given_name": "Pawan", "family_name": "Kumar", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-02T13:09:11Z", "noun_phrases": [ "Nrf2", "Aryl Hydrocarbon Receptor", "IL-22 Response", "CD4+ T Cells" ], "doi": "10.4049/jimmunol.1900656", "access": "open", "takeaways": " CDDO-Im, a specific Nrf2 activator, promotes IL-17A and IL-22 responses in murine Th17 cells . In contrast, CDDO inhibits IL-16 response in multiple sclerosis patient-derived PBMCs . Nrf 2 acts through the regulation of antioxidant response element binding motifs .", "categories": [] } ] }